Article (Scientific journals)
Le medicament du mois. Exenatide (Byetta). Incretinomimetique indique dans le traitement du diabete de type 2 apres echec et en complement des antidiabetiques oraux.
Scheen, André; Van Gaal, L. F.
2008In Revue Médicale de Liège, 63 (3), p. 158-65
Peer reviewed
 

Files


Full Text
200803_10.pdf
Publisher postprint (1.19 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Diabetes Mellitus, Type 2/drug therapy; Drug Therapy, Combination; Humans; Hypoglycemic Agents/pharmacology/therapeutic use; Peptides/pharmacology/therapeutic use; Venoms/pharmacology/therapeutic use
Abstract :
[en] Exenatide (Byetta) is a synthetic derivative of exendin-4 and an agonist of receptors of glucagon-like peptide-1 (GLP-1). It is resistant to the rapid inactivation by dipeptidylpeptidase-4 and acts as an incretin mimetic. It stimulates insulin secretion by the B cell in a glucose-dependent manner whereas it inhibits glucagon secretion. Exenatide improves mainly postprandial glucose concentrations and lowers glycated haemoglobin (HbA(1c)) levels, without being directly responsible for hypoglycaemia or requiring mandatory home blood glucose monitoring. Furthermore, it slows down gastric emptying and promotes sustained body weight reduction, even in absence of frequently reported nausea following treatment initiation. Exenatide is recommended and reimbursed in Belgium for the treatment of type 2 diabetes, in combination with metformin and a sulfonylurea, in patients not adequately controlled with maximal tolerated doses of these oral glucose-lowering agents. Exenatide is presented as pre-filled pens for subcutaneous injection. The recommended initial dose is 5 microg before morning and evening meals, to be up titrated to 10 microg twice daily. Exenatide may represent a valuable alternative to insulin therapy, especially in overweight or obese patients with type 2 diabetes and not ready to perform home blood glucose monitoring.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Van Gaal, L. F.
Language :
French
Title :
Le medicament du mois. Exenatide (Byetta). Incretinomimetique indique dans le traitement du diabete de type 2 apres echec et en complement des antidiabetiques oraux.
Alternative titles :
[en] Medication of the month...Exenatide (Byetta) incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents
Publication date :
2008
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
63
Issue :
3
Pages :
158-65
Peer reviewed :
Peer reviewed
Available on ORBi :
since 10 December 2008

Statistics


Number of views
950 (10 by ULiège)
Number of downloads
1701 (4 by ULiège)

Scopus citations®
 
12
Scopus citations®
without self-citations
2

Bibliography


Similar publications



Contact ORBi